Wells Fargo Maintains Overweight on Mastercard, Lowers Price Target to $400
Wells Fargo analyst Donald Fandetti maintains Mastercard (NYSE:MA) with a Overweight and lowers the price target from $450 to $400.
Wells Fargo Maintains Equal-Weight on Discover Financial, Lowers Price Target to $103
Wells Fargo analyst Donald Fandetti maintains Discover Financial (NYSE:DFS) with a Equal-Weight and lowers the price target from $130 to $103.
Wells Fargo Maintains Overweight on Capital One Financial, Lowers Price Target to $130
Wells Fargo analyst Donald Fandetti maintains Capital One Financial (NYSE:COF) with a Overweight and lowers the price target from $160 to $130.
Wells Fargo Maintains Overweight on American Express, Lowers Price Target to $190
Wells Fargo analyst Donald Fandetti maintains American Express (NYSE:AXP) with a Overweight and lowers the price target from $215 to $190.
Credit Suisse Maintains Outperform on Kura Oncology, Raises Price Target to $29
Credit Suisse analyst Tiago Fauth maintains Kura Oncology (NASDAQ:KURA) with a Outperform and raises the price target from $27 to $29.
Credit Suisse Maintains Neutral on PepsiCo, Raises Price Target to $170
Credit Suisse analyst Kaumil Gajrawala maintains PepsiCo (NASDAQ:PEP) with a Neutral and raises the price target from $168 to $170.
Raymond James Maintains Outperform on Leap Therapeutics, Lowers Price Target to $3
Raymond James analyst Steven Seedhouse maintains Leap Therapeutics (NASDAQ:LPTX) with a Outperform and lowers the price target from $4 to $3.
Raymond James Maintains Strong Buy on Dave & Buster’s Enter, Lowers Price Target to $55
Raymond James analyst Brian Vaccaro maintains Dave & Buster's Enter (NASDAQ:PLAY) with a Strong Buy and lowers the price target from $60 to $55.
Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $45
Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $40 to $45.
Wells Fargo Maintains Equal-Weight on Honeywell Intl, Lowers Price Target to $180
Wells Fargo analyst Joseph O'Dea maintains Honeywell Intl (NASDAQ:HON) with a Equal-Weight and lowers the price target from $183 to $180.